October 25, 2023

A Global Phase 3 Clinical Trial of MT-2111 in Combination with Rituximab
has been started in Japan
Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative
Director: Akihiro Tsujimura; hereinafter, “MTPC”), a member of the Mitsubishi ChemicalGroup, today announced a global Phase 3 clinical trial (LOTIS-5, NCT04384484) of MT2111, ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in secondline or later, transplant ineligible patients with diffuse large B-cell lymphoma (DLBCL) hasbeen started in Japan.
In April 2021, ZYNLONTA® was granted accelerated approval by the U.S. Food and Drug
Administration (FDA) as the first and only CD19-targeted antibody drug conjugate (ADC)
as a single-agent treatment for adult patients with r/r DLBCL after two or more lines ofsystemic therapy. In January 2022, MTPC entered into an exclusive license agreement with
ADC Therapeutics SA (NYSE: ADCT) for the development and commercialization ofZYNLONTA® for all hematologic and solid tumor indications in Japan. A Phase 1/2 clinicalstudy (MT-2111-A-101, NCT05658562) with MT-2111 monotherapy in patients with r/r
DLBCL in Japan is currently underway.
“We are thrilled to have reached this important milestone. Because of their age orcomorbidities, a significant proportion of patients may be ineligible for autologous stem celltransplantation,” said Hideki Kuki, Head of Ikuyaku. Integrated Value Development Divisionof MTPC. “This represents an initial step in our commitment to advancing this project as
rapidly as possible to potentially transform the lives of patients in critical need, with the goalof delivering a new treatment option.”“We are excited by the progress our partner in Japan has made in the ZYNLONTA®
development program,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.
“This is an important part of our global effort to bring this differentiated treatment option toappropriate patients with DLBCL with significant unmet medical needs around the world.”
LOTIS-5 is a global Phase 3 clinical trial of ZYNLONTA® combined with rituximab versus
immunochemotherapy in patients with relapsed or refractory diffuse large B-Cell lymphoma(r/r DLBCL).
Leveraging its strengths in drug discovery, MTPC will take on the new challenge ofoncology and strive to bring new treatments options to patients suffering from cancer.

Contact:
Mitsubishi Chemical Group Corporation
Corporate Communications Division
Osaka Corporate Communications Department+81-6-6205-5119
1/2

■About MT-2111, ZYNLONTA® (loncastuximab tesirine-lpyl)
MT-2111 is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19expressing cell, MT-2111 is internalized by the cell, where enzymes release apyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove withlittle distortion, remaining less visible to DNA repair mechanisms. This ultimately results incell cycle arrest and tumor cell death.
The U.S. Food and Drug Administration (FDA) has approved ZYNLONTA® (loncastuximabtesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell
lymphoma after two or more lines of systemic therapy, including diffuse large B-cell
lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade
lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum ofheavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat
disease, including patients who did not respond to first-line therapy, patients refractory toall prior lines of therapy, patients with double/triple hit genetics and patients who had stem
cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA®. This indication
is approved by the FDA under accelerated approval and in the European Union underconditional approval based on overall response rate and continued approval for thisindication may be contingent upon verification and description of clinical benefit in aconfirmatory trial.
ZYNLONTA® is also being evaluated as a therapeutic option in combination studies in otherB-cell malignancies and earlier lines of therapy.
■About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company
improving the lives of those affected by cancer with its next-generation, targeted antibody
drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADCtechnology to transform the treatment paradigm for patients with hematologic malignancies
and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) isapproved by the FDA for the treatment of relapsed or refractory diffuse large B-cell
lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents. In addition to ZYNLONTA, ADC Therapeutics has multiple
ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations inLondon, the San Francisco Bay Area and New Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

2/2